British Airways Pensions Investment Management Ltd held its stake in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 379,490 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Celgene Corporation accounts for about 1.4% of British Airways Pensions Investment Management Ltd’s investment portfolio, making the stock its 17th largest holding. British Airways Pensions Investment Management Ltd’s holdings in Celgene Corporation were worth $49,256,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Pictet Asset Management Ltd. lifted its holdings in Celgene Corporation by 6.3% in the second quarter. Pictet Asset Management Ltd. now owns 2,408,975 shares of the biopharmaceutical company’s stock valued at $275,611,000 after buying an additional 143,658 shares during the period. Honeywell International Inc. lifted its holdings in Celgene Corporation by 9.9% in the second quarter. Honeywell International Inc. now owns 277,900 shares of the biopharmaceutical company’s stock valued at $36,091,000 after buying an additional 25,000 shares during the period. Beach Investment Management LLC. lifted its holdings in Celgene Corporation by 1,935.3% in the second quarter. Beach Investment Management LLC. now owns 126,188 shares of the biopharmaceutical company’s stock valued at $16,388,000 after buying an additional 119,988 shares during the period. Trust Investment Advisors lifted its holdings in Celgene Corporation by 10.7% in the second quarter. Trust Investment Advisors now owns 5,175 shares of the biopharmaceutical company’s stock valued at $672,000 after buying an additional 500 shares during the period. Finally, Novare Capital Management LLC lifted its holdings in Celgene Corporation by 0.6% in the second quarter. Novare Capital Management LLC now owns 48,519 shares of the biopharmaceutical company’s stock valued at $6,301,000 after buying an additional 275 shares during the period. 79.36% of the stock is currently owned by institutional investors.

Celgene Corporation (NASDAQ:CELG) opened at 139.21 on Friday. The company has a market capitalization of $108.91 billion, a P/E ratio of 43.11 and a beta of 1.88. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $147.17. The stock’s 50 day moving average is $139.31 and its 200-day moving average is $129.53. Celgene Corporation also was the recipient of unusually large options trading activity on Thursday. Investors bought 12,607 put options on the company. This represents an increase of 260% compared to the typical volume of 3,499 put options.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same period in the previous year, the business posted $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

Several equities analysts recently issued reports on the stock. Morgan Stanley lowered shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Thursday. Royal Bank Of Canada restated a “buy” rating and issued a $173.00 target price on shares of Celgene Corporation in a report on Thursday. Robert W. Baird restated a “buy” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Thursday, September 21st. Cantor Fitzgerald restated a “buy” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Tuesday, September 26th. Finally, Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and twenty-two have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $150.60.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/british-airways-pensions-investment-management-ltd-has-49256000-holdings-in-celgene-corporation-celg/1614265.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock valued at $6,268,259 over the last quarter. Company insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.